logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line

< Back

Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line

Drugs

Cancer and Palliative Care

January 2021


Nivolumab in combination with ipilimumab is in development for cisplatin-ineligible patients with previously untreated, unresectable or metastatic urothelial cancer (UC). UC occurs on the lining of the renal pelvis, ureter, bladder and urethra, and other parts of the urinary system. Metastatic UC occurs when the cancer has spread to other parts of the body. Durable responses are rare with current standard of care treatments. Therefore, treatment approaches with longer-term disease control and extending to broader metastatic UC patient populations are needed.
Nivolumab and ipilimumab, administered IV, are immune therapy medicinal products that are currently licensed as a combination treatment of advanced cancers. Nivolumab is an immune checkpoint inhibitor. It works by improving the activity of white blood cells (T-cells), thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab has a different mode of action but also increases the activity of T-cells against cancer cells. If licensed, nivolumab in combination with ipilimumab may offer an additional first line treatment option for cisplatin-ineligible patients with previously untreated, unresectable or metastatic UC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts